Nedaplatin: A Radiosensitizing Agent for Patients with Cervical Cancer

Table 6

Literature review: survival, treatment failure, and complications.

Author (Reference)	Year	Study type	Concurrent chemotherapy	Brachytherapy	Stage	Followup	Overall Survival (%)	Treatment Failure (%)	Late toxicity (grade 3-4) (%)
T. Teshima [22]	1993	RCT	—	HDR	III	5 years	53	47	10
M. Hareyama [23]	2002	RCT	—	HDR	III	5 years	69	49	7
P. Lertsanguansinchai [24]	2004	RCT	—	HDR	IIIb	3 years	71	30	7
M. Morris [25]	1999	RCT	Cisplatin	LDR	III-IVa	5 years	63	42	12
P. G. Rose [26]	1999	RCT	Cisplatin	LDR	II-IVa	4 years	66	38	1.7
T. Toita [27]	2005	Retro	Cisplatin	HDR	I-III	3 years	79	33	2
Y. L. Chung [28]	2005	Phase I/II	Cisplatin	HDR	IIb-IVa	3 years	83	19	6
S. W. Chen [29]	2006	Retro	Cisplatin	HDR	IIb-III	4 years	74	46	14
R. Potter [30]	2006	Retro	Cisplatin	HDR	Ib-IVa	3 years	61	44	4
P. Novetsky [31]	2007	Retro	Cisplatin	HDR	III-IV	5 years	65	35	6
S. Mabuchi [20]	2010	Retro	Nedaplatin	HDR	IIIb	5 years	65	35	10

RCT: randomized controlled study, Retro: retrospective study, HDR: high-dose rate brachytherapy, LDR: low-dose rate brachytherapy.